Clinical Trial

Molecular and Functional Imaging in Monogenic PD.

Study acronym: FOX_1
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 7, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this study, the investigators aim to find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of PD symptoms.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-08-24; most recent amendment 2025-10-01.
Trial Details
NCT Number NCT05518617
Lead Sponsor University of Exeter
Conditions Parkinson Disease, Nervous System Disorder, Neurodegenerative Diseases, Neurodegenerative Disease, Hereditary, Parkinson's
Enrollment 45 participants
Start Date 2022-07-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-07